NovaLead’s Revolutionary Drug Approved By CDSCO For Diabetic Foot Ulcer Treatment In India

PUNE: Pune-based NovaLead’s Patented Repurposed Drug receives approval from CDSCO for the treatment of Diabetic Foot Ulcer (DFU) for the Indian market. NovaLead Pharma Private Limited (NovaLead), the pioneer of drug repurposing in India announced today that the drug regulator in India, CDSCO has approved their patented Repurposed Drug for the treatment of Diabetic Foot Ulcer (DFU) which is a global unmet medical need.

With over 15% -25% of diabetic patients suffering from DFU at least once in their lifetime, DFU is the most prevalent complication caused by chronic diabetes. The approval of NovaLead’s patented repurposed drug is significant because DFU is the leading cause of lower limb amputations globally, with about 100,000 annual incidences in India alone.

“The approval of this drug marks an important moment for people suffering from DFU, who until now had limited drug options for complete wound closure. Approval of this drug is also a demonstration of effective Public-Private partnership as its development was partly funded by BIRAC, a govt. of India initiative.” said Supreet Deshpande, Chief Executive Officer at NovaLead Pharma Pvt. Ltd., Pune – India.

“Although it is a repurposed drug, we developed it as a new drug with comprehensive preclinical and clinical investigations, keeping patient safety at the forefront. Its approval is based on statistically significant positive results over the standard of care treatment in a randomized, double-blind Phase 3 clinical trial,” said Dr. Sudhir Kulkarni, Vice President- of Discovery, at NovaLead.

This drug is a novel topical gel formulation of Esmolol hydrochloride, which is already approved in several countries for cardiac conditions via intravenous injection. Thus, this novel topical gel discovered and developed by NovaLead is a new indication as well as a new formulation to be first launched in India. NovaLead has been granted patents for this drug in several countries including regulated markets of the USA, EU, and Japan.

Atul Aslekar, COO of NovaLead, mentioned that “a start-up traversing the highly challenging drug development cycle right from discovery to approval, spanning over a decade and a half, makes NovaLead a unique success story in Indian pharma”.

“The drug will be made available to the patients of DFU in India by one of the leading Indian pharmaceutical companies through an exclusive IP licensing arrangement with NovaLead. Going forward, NovaLead will focus on the development of this repurposed drug for regulated markets of USA and Europe,” said Supreet Deshpande.